1.1 Scope of Research

1.2 Research Methodology

2.1 Transferring Cost Efficiencies across the Value Chain

2.2 IP Filings Focus on Minimally Invasive Therapies

2.3 Clinical Trials to Diversify Product Pipeline

2.4 Differentiate Products by Building a Value-driven Organization

3.1 Invasive, Minimally Invasive and Non-Invasive Neuromodulation Technologies

3.2 High Market Demand for Non-Invasive Methods and Therapies for Lifestyle Disorders

3.3 Spinal Cord and Deep Brain Stimulation Systems, Global, 2016

3.4 Vagus Nerve and Other Stimulation Systems, Global, 2016

3.5 NPD Efforts Focus on Miniaturization of Implants

3.6 Objectives of OEMs Are Aligned to Delivering Personalized Value to Payers

3.7 Focus on Creating Effective Collaboration among Payers Drive Channel Growth

3.8 Neuromodulation Systems, Prices, Global, 2016

3.9 Assessment of Components of Neuromodulation Systems

3.10 Analytical Hierarchy Process: Prioritization of Neuromodulation Technologies

3.11 Performance of Pulse Generator and Lead Precision Is of High Priority

3.12 Functionality of Device Controller and Programmer Are of Least Priority

3.13 Improving the Longevity of Power Supplies and Lead Flexibility

3.14 Payer Preference to Minimally Invasive Therapies for Chronic Conditions

4.1 80% of Market Share Is Owned by Four Companies

4.2 Cost-efficient Value Chain and Consolidation Efforts Drive Profitable Growth

4.3 Better Patient-Physician Collaboration Drive Technology Growth

4.4 Consolidation Trends Pull Prospective Investments within the Global Industry

4.5 OEMs Race against VC/PE Firms to Invest in Neuromodulation Technologies

4.6 Increase in Cross-selling Agreements with Pharmaceutical Companies

4.7 OEMs Place a Premium during Commercialization of Co-created Products

4.8 Established Mid-size Firms Are Partnership Targets in Emerging Markets

4.9 Backward Integration Efforts of OEMs Will Deliver Personalized Value

4.10 VC and Major Pharmaceutical Firms Influence Growth in Delivery of Quality Care

5.1 Centricity between Cost Efficiency and Market Maturity Enabled Customer Value

5.2 Neuromodulation: Key Growth Strategies for a Value-Driven Business Model, Global, 2016

5.3 Value-for-Cost Business Model: OEMs Focus on Cost Savings within the Value-Chain

6.1 A Robust Operations Analytics Framework to Drive Quality Patient Care

6.2 Strategic Partnerships Deliver Sustainable Growth and Value Proposition

7.1 Boston Scientific Leads in IP Creation Activities Worldwide

7.2 Key Patents: Cantilever Electrodes for Transdermal and Transcranial Stimulation

7.3 Key Patents: Optogenetic Therapies for Movement Disorders

7.4 Key Patents: Minimally Invasive Implantable Neurostimulation Systems

7.5 List of Key Industry Participants

Legal Disclaimer

8.1 Analytical Hierarchical Process

8.2 Explanation of Benchmarking Criteria

8.3 Liberatore’s Rating Scale

9.1 The Frost & Sullivan Story

9.2 Value Proposition: Future of Your Company & Career

9.3 Global Perspective

9.4 Industry Convergence

9.5 360º Research Perspective

9.6 Implementation Excellence

9.7 Our Blue Ocean Strategy